| 產(chǎn)品編號(hào) | bs-7110R-BF594 |
| 英文名稱 | Rabbit Anti-DOCK1/BF594 Conjugated antibody |
| 中文名稱 | BF594標(biāo)記的細(xì)胞質(zhì)分裂付出蛋白1抗體 |
| 別 名 | 180 kDa protein downstream of CRK; Ced5; Dedicator of Cytokinesis 1; Dedicator of cytokinesis protein 1; DOCK 1; DOCK-1; DOCK 180; DOCK1; DOCK1_HUMAN; DOCK180. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 細(xì)胞自噬 G蛋白信號(hào) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 215kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human DOCK1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Tissue specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Function: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Subunit: Interacts with the SH3 domains of CRK and NCK2 via multiple sites. Interacts with nucleotide-free RAC1 via its DHR-2 domain. Interacts with ELMO1, ELMO2 and probably ELMO3 via its SH3 domain. Interacts with RAC1 and BAI1. Subcellular Location: Cytoplasm (Probable). Membrane (Probable). Note=Recruited to membranes via its interaction with phosphatidylinositol 3,4,5-trisphosphate (Probable). Tissue Specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Similarity: Belongs to the DOCK family. Contains 1 DHR-1 domain. Contains 1 DHR-2 domain. Contains 1 SH3 domain. Database links: Entrez Gene: 1793 Human Entrez Gene: 330662 Mouse Omim: 601403 Human SwissProt: Q14185 Human SwissProt: Q8BUR4 Mouse Unigene: 159195 Human Unigene: 645702 Human Unigene: 436572 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 乳腺癌轉(zhuǎn)移的新標(biāo)記物DOCK1 乳腺癌是一種常常發(fā)生轉(zhuǎn)移的癌癥。將近90%的乳腺癌患者都因?yàn)榘┌Y擴(kuò)散而死，因此，理解這一危險(xiǎn)過(guò)程的細(xì)胞和分子基礎(chǔ)機(jī)制是十分重要的。 近日，加拿大蒙特利爾臨床研究所（Institut de recherches cliniques de Montreal, IRCM）的科學(xué)家在乳腺癌研究方面取得了一個(gè)重要的發(fā)現(xiàn)，他們確定了，一種名為DOCK1的蛋白質(zhì)可以作為潛在的靶標(biāo)用于減少乳腺癌患者的癌轉(zhuǎn)移。相關(guān)研究結(jié)果刊登在了近期出版的《PNAS》上。 研究人員在乳腺癌治療方面盡管已經(jīng)取得了重要的進(jìn)展，但是對(duì)于癌癥擴(kuò)散的機(jī)制卻知之甚少?？茖W(xué)家正在試圖確定能夠調(diào)節(jié)癌轉(zhuǎn)移過(guò)程的蛋白質(zhì)，因?yàn)樗鼈兓蛟S可以作為新的藥物靶標(biāo)，并與現(xiàn)有的方法相結(jié)合促進(jìn)治療的效果。 在這項(xiàng)研究中，2個(gè)主要的癌癥亞型——HER-2+型和Basal-like型，很容易轉(zhuǎn)移和復(fù)發(fā)，并最終導(dǎo)致患者的低生存率。該調(diào)查以HER-2+(人類表皮生長(zhǎng)因子受體2)型為研究對(duì)象， 這代表了大約25%的乳腺癌病例。 HER2陽(yáng)性腫瘤比其它類型的腫瘤更傾向于快速的發(fā)展和擴(kuò)散。 研究人員解釋到，通過(guò)研究HER2+乳腺癌小鼠模型，確定了DOCK1蛋白質(zhì)是癌轉(zhuǎn)移的一個(gè)重要的調(diào)控因子。當(dāng)去除了小鼠中的這一蛋白質(zhì)后，乳腺癌的肺轉(zhuǎn)移大大減少了。此外，研究發(fā)現(xiàn)DOCK1蛋白質(zhì)有助于腫瘤的生長(zhǎng)。 為了證明DOCK1的表達(dá)與乳腺癌預(yù)后之間的關(guān)系，研究人員對(duì)包含患者基因信息的幾個(gè)數(shù)據(jù)庫(kù)進(jìn)行了分析。結(jié)果發(fā)現(xiàn)，在HER-2+型或Basal-like型乳腺癌中，高水平的DOCK1與較差的預(yù)后以及疾病的復(fù)發(fā)有關(guān)。 |
